Seneca biopharma, inc. (CUR)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Sep'10Jun'10
Revenues

6

2

2

7

2

2

2

252

2

252

2

2

2

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Revenues

-

-

-

-

-

-

-

-

-

-

-

-

-

8

2

2

2

2

2

2

2

4

5

5

4

2

2

2

102

2

170

78

156

-

103

0

-

-

0

Operating expenses:
Research and development expenses

696

767

825

954

1,514

878

897

1,014

1,169

1,225

1,383

2,585

2,902

4,025

3,589

2,474

3,065

2,749

3,392

3,312

3,182

2,621

2,109

1,999

1,630

1,783

1,847

1,906

1,748

1,699

1,385

1,598

1,422

1,406

2,124

2,085

1,738

2,112

2,613

General and administrative expenses

1,299

1,368

1,301

971

944

928

1,188

1,260

1,182

1,296

1,206

1,635

1,332

1,634

1,329

1,362

3,170

1,604

1,807

1,684

1,433

2,024

2,001

1,516

3,550

1,163

1,707

1,281

1,195

982

1,280

821

1,162

1,405

1,137

1,523

1,772

1,769

1,550

Depreciation and amortization

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

81

50

50

46

87

41

34

37

64

59

25

42

30

Total operating expenses

1,996

2,135

2,126

1,926

2,459

1,807

2,085

2,275

2,351

2,521

2,590

4,220

4,234

5,660

4,919

3,836

6,236

4,353

5,200

4,997

4,615

4,645

4,111

3,516

5,181

2,765

3,636

3,238

2,994

2,729

2,753

2,461

2,619

2,849

3,326

3,668

3,536

3,923

4,195

Operating loss

-1,990

-2,132

-2,124

-1,918

-2,456

-1,804

-2,082

-2,022

-2,348

-2,268

-2,587

-4,218

-4,232

-5,651

-4,917

-3,834

-6,233

-4,351

-5,197

-4,994

-4,612

-4,640

-4,106

-3,511

-5,176

-2,762

-3,633

-3,235

-2,891

-2,726

-2,583

-2,383

-2,463

-2,562

-3,223

-3,668

-3,536

-3,923

-4,195

Other income (expense):
Litigation settlement

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

250

-

-

Interest income

13

12

15

10

29

23

17

19

17

17

18

14

20

16

17

13

11

15

24

16

13

12

13

17

24

22

18

16

9

12

5

7

8

6

11

20

22

17

9

Interest expense

2

4

1

0

2

3

1

0

1

3

1

15

138

191

240

322

386

439

464

459

453

428

361

397

432

457

448

439

48

0

0

0

0

-

0

0

-

0

1

Warrant inducement expense

5,620

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain (loss) on fair value of liability classified warrants

24

82

320

436

-340

1,463

236

1,378

190

-1,067

2,679

-341

-2,741

441

-538

757

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain on related party settlement

-

-

-

-

-

-

-

-

-

-

-

-

-

-

458

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Fees related to issuance of liability classified warrants and other expenses

-

-

-

-

-

-

-

-

-

-6

242

87

476

10

0

466

-3

-

0

10

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Warrant modification expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

3,109

-

0

1,945

2,405

666

0

0

0

0

-

-

-

-

-

-

Loss from change in fair value of derivative instruments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

334

105

677

188

-6

-

0

0

-

-

-

-

-

-

-

Other expense

-

-

26

34

-344

-

0

-1

-4

-

-

-

-

-

-

-

-

-

-

-

0

-250

0

250

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Litigation settlement

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

Gain from change in fair value of derivative instruments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

0

161

-23

-764

Other income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

2

-

-

-

-

-

-

Litigation Settlement

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

Total other income (expense)

-5,584

94

361

481

-657

1,484

252

1,395

202

-1,046

2,454

-430

-3,335

255

-303

-18

-372

-413

-440

-453

-440

-862

-348

-3,240

-742

-540

-3,052

-3,016

-698

11

5

6

10

5

11

20

434

-6

-756

Net loss

-7,575

-2,037

-1,763

-1,436

-3,113

-320

-1,830

-627

-2,146

-3,315

-133

-4,649

-7,567

-5,396

-5,220

-3,852

-6,605

-4,765

-5,637

-5,448

-5,053

-5,503

-4,455

-6,751

-5,919

-3,303

-6,686

-6,251

-3,590

-2,714

-2,577

-2,376

-2,452

-2,556

-3,211

-3,648

-3,101

-3,930

-4,951

Net loss per share - basic (in dollars per share)

-

-

-

-

-

-

-

-

-

-

-0.01

-

-

-

-0.59

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss per share - diluted (in dollars per share)

-

-

-

-

-

-

-

-

-

-

-0.18

-

-

-

-0.59

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Weighted average common shares outstanding - basic (in shares)

-

-

-

-

-

-

-

-

-

-

14,060

-

-

-

8,835

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Weighted average common shares outstanding - diluted (in shares)

-

-

-

-

-

-

-

-

-

-

14,163

-

-

-

8,835

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss per share - basic and diluted (in dollars per share)

-0.93

1.66

-0.59

-1.45

-3.42

-4.16

-2.41

-0.83

-0.14

-

-

-0.39

-0.68

-

-

-0.47

-0.93

-2.81

-0.06

-0.06

-0.06

-0.06

-0.05

-0.08

-0.07

-0.04

-0.09

-0.09

-0.05

-0.04

-0.04

-0.04

-0.05

-0.04

-0.07

-0.08

-0.07

-0.09

-0.12

Weighted average common shares outstanding - basic and diluted (in shares)

8,139

3,909

2,975

993

910

-14,019

758

757

15,116

-

-

11,906

11,140

-

-

8,141

7,077

-244,056

91,569

90,791

89,654

88,042

87,366

87,186

85,750

77,564

72,986

69,864

68,700

68,732

58,363

54,086

51,433

-

48,488

48,486

-

-

-

Comprehensive loss:
Net loss

-7,575

-2,037

-1,763

-1,436

-3,113

-320

-1,830

-627

-2,146

-3,315

-133

-4,649

-7,567

-5,396

-5,220

-3,852

-6,605

-4,765

-5,637

-5,448

-5,053

-5,503

-4,455

-6,751

-5,919

-3,303

-6,686

-6,251

-3,590

-2,714

-2,577

-2,376

-2,452

-2,556

-3,211

-3,648

-3,101

-3,930

-4,951

Foreign currency translation adjustment

-0

1

-4

-1

-1

-1

-0

-1

0

0

-1

-0

-0

-0

0

3

-1

-

-2

-0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comprehensive loss

-7,576

-2,036

-1,767

-1,437

-3,115

-321

-1,830

-628

-2,146

-3,315

-134

-4,649

-7,567

-5,396

-5,220

-3,849

-6,607

-

-5,639

-5,448

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Foreign currency translation adjustment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-0

0

0

-1

1

6

0

0

-

0

-

-

-

-

-

-

-

-

Comprehensive loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-5,053

-5,503

-4,455

-6,751

-5,920

-3,302

-6,680

-6,251

-3,590

-

-2,577

-

-

-

-

-

-

-

-

Weighted average common shares outstanding - basic and diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

47,692

46,163

42,450